Double Blind, Two Dose, Cross-over Clinical Trial of the Positive Allosteric Modulator at the alpha7 Nicotinic Cholinergic Receptor AVL-3288 in Schizophrenia Patients

Trial Profile

Double Blind, Two Dose, Cross-over Clinical Trial of the Positive Allosteric Modulator at the alpha7 Nicotinic Cholinergic Receptor AVL-3288 in Schizophrenia Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs AVL 3288 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 1 May 2018 to 1 Oct 2018.
    • 09 Apr 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Aug 2018.
    • 09 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top